Drug Trial Radar · NCT01526785
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
Last checked: Nov 20, 2026Latest source record: Dec 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
113
Actual
Start
Mar 2012
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.
Conditions
- Pompe Disease
Interventions
Alglucosidase alfaDrug
4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Clinically Stable or Improved at Week 52Time frame: Week 52
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Oakland, California
Site not named
Orange, California
Site not named
San Diego, California
Site not named
San Jose, California
Site not named
Stanford, California
Site not named
Aurora, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Gainesville, Florida
Site not named
Miami, Florida
Site not named
Decatur, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Jackson, Mississippi
Site not named
Columbia, Missouri
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
New Brunswick, New Jersey
Site not named
Glens Falls, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Valhalla, New York
Site not named
Asheville, North Carolina
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Philadelphia, Pennsylvania
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.